| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Clinical Officer
1 company
Jason Paul Steik is Chief Clinical Officer at PNTG. Jason Paul Steik's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $622K at current prices.
The PNTG filings lean toward selling, a net 1,394 shares.
Jason Paul Steik has 2 Form 4 filings on record from March 2026 to August 2026, all as Chief Clinical Officer at The Pennant Group (PNTG), 2026.
The 2 reported transactions were 1 open-market sale and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $54K.
The only open-market sale was 1,394 shares of PNTG at an average $38.52 on August 6, 2026, about $54K.